Evaluation of the effectiveness of the herbal preparations in the treatment of patients with non-erosive gastroesophageal reflux disease

Background. In the treatment of gastroesophageal reflux disease, patients are usually advised to make lifestyle changes and prescribe drugs from the proton pump inhibitor family, but drug-resistant gastroesophageal reflux disease is becoming an increasingly common problem. In addition to the growing resistance of gastroesophageal reflux disease to therapy with proton pump inhibitors, the safety of long-term therapy with drugs of this group has been increasingly discussed in recent years. In this regard, the question arises about finding safe alternative ways to get rid of clinical manifestations of the disease at uncomplicated stages of the course in patients with gastroesophageal reflux disease.

Objective. Evaluation of the effectiveness of the use of the herbal preparation (biologically active supplement) Liv Lively in patients with non-erosive reflux disease.

Materials and methods. 40 patients with non-erosive reflux disease were examined, who were tested before and 1 month after therapy with the herbal preparation using the RSI, GSRS (Russian version) and MOS SF-36 questionnaires.

Results. In the examined patients, 1 month after treatment with the herbal preparation, there was a statistically significant decrease in the intensity of such esophageal and extraesophageal symptoms of the disease as hoarseness or voice change (р = 0.000057), coughing, perspiration, mucus formation or postnasal congestion, a feeling of the foreign body in the, as well as heartburn, burning sensation behind the sternum, in the esophagus, chest pain, digestive disorder (р = 0.000001). After treatment, there was a statistically significant decrease in the total score of the GSRS questionnaire, as well as in such indicators as abdominal pain, gastroesophageal reflux disease syndrome itself, as well as dyspeptic syndrome and constipation syndrome (р = 0.000001). In 1 month after the therapy, there was a statistically significant improvement in such indicators of the SF-36 questionnaire as the state of health in general and at the moment (p = 0.00001), improved tolerance to heavy physical exertion (р = 0.00001), as well as the general physical and emotional state, the indicator of physical pain and the tendency to feel susceptible to diseases (р = 0.000012).

1. Shaqran T. M., Ismaeel M. M., Alnuaman A. A., Al Ahmad F. A., Albalawi G. A., Almubarak J. N., AlHarbi R. S., Alaqidi R. S., AlAli Y. A., Alfawaz K. S., Daghriri A. A. Epidemiology, Causes, and Management of Gastro-esophageal Reflux Disease: A Systematic Review. Cureus. 2023; 15 (10): e47420. DOI: 10.7759/cureus.47420.

2. Haastrup P. F., Thompson W., Søndergaard J., Jarbøl D. E. Side Effects of Long-Term Proton Pump Inhibitor Use: A Review. Basic Clin Pharmacol Toxicol. 2018; 123 (2): 114-121. DOI: 10.1111/bcpt.13023.

3. Castellana C., Pecere S., Furnari M., Telese A., Matteo M. V., Haidry R., Eusebi L. H. Side effects of long-term use of proton pump inhibitors: practical considerations. Pol Arch Intern Med. 2021; 131 (6): 541-549. DOI: 10.20452/pamw.15997.

4. Gommers L. M. M., Hoenderop J. G. J., de Baaij J. H. F. Mechanisms of proton pump inhibitor-induced hypomagnesemia. Acta Physiol (Oxf). 2022; 235 (4): e13846. DOI: 10.1111/apha.13846.

5. Kiecka A., Szczepanik M. Proton pump inhibitorinduced gut dysbiosis and immunomodulation: current knowledge and potential restoration by probiotics. Pharmacol Rep. 2023; 75 (4): 791-804. DOI: 10.1007/s43440-023-00489-x.

6. Fossmark R., Ness-Jensen E., Sørdal Ø. Is empiric proton pump inhibition in patients with symptoms of extraesophageal gastroesophageal reflux justified? BMC Gastroenterol. 2023; 23 (1): 303. DOI: 10.1186/s12876-023-02945-

7. Kim E., Kim S., Suh H. S. Use of gastrointestinal prokinetics and the risk of parkinsonism: A population-based case-crossover study. Pharmacoepidemiol Drug Saf. 2023; 32 (12): 1378-1386. DOI: 10.1002/pds.5668.

8. Junqueira D. R., Bennett D., Huh S. Y., Casañas I., Comabella C. Clinical Presentations of Drug-Induced Hyperprolactinaemia: A Literature Review. Pharmaceut Med. 2023; 37 (2): 153-166. DOI: 10.1007/s40290-023-00462-2.

9. Fauzi A., Simadibrata D. M., Friska D., Syam A. F. COVID-19 Pandemic is Associated With Increased Prevalence of GERD and Decreased GERD-related Quality of Life: Analysis From 9800 Participants in the Indonesian GERD-Q Study. J Clin Gastroenterol. 2024; 58 (4): 324-329. DOI: 10.1097/MCG.0000000000001923.

10. Nacci A., de Bortoli N., Capobianco S., Simoni F., Giusti T., Visaggi P., Barillari M. R., Savarino E. V., Frazzoni M., Berrettini S., Fattori B., Bastiani L. The Revised Reflux Symptom Index (R-RSI): Development, Internal and External Validation Study. Folia Phoniatr Logop. 2024; 18: 1-13. DOI: 10.1159/000540233.

11. Baryshnikova N., Belousova L., Petrenko V., Pavlova E. Assessment of quality of life in gastroenterological patients. Vrach 2013; 7: 62-65. (In Russ.)

12. Prananda A. T., Dalimunthe A., Harahap U., Simanjuntak Y., Peronika E., Karosekali N. E., Hasibuan P. A. Z., Syahputra R. A., Situmorang P. C., Nurkolis F. Phyllanthus emblica: a comprehensive review of its phytochemical composition and pharmacological properties. Front Pharmacol. 2023; 14: 1288618. DOI: 10.3389/fphar.2023.1288618.

13. Mal A.., Meena D. S. Phyllanthus emblica: a herbal remedy for healthy life. ECS Trans. 2022; 107 (1): 3199-3206. DOI: 10.1149/10701.3199ecst.

14. Musial C., Kuban-Jankowska A., Gorska-Ponikowska M. Beneficial Properties of Green Tea Catechins. Int J Mol Sci. 2020; 21 (5): 1744. DOI: 10.3390/ijms21051744.